tbuckley/cabot-search huggingface dataset:
AB0933 Treg/Th17 Cells and High Resolution Ultrasound Inflammatory Findings in Established Rheumatoid Arthritis: A Cross Sectional Study
Authors: A.D. Do Prado, T.S. Baptista, L. Petersen, M.E. Bauer, M.C. Bisi, M. Bredemeier, D.M. Piovesan, I.G. da Silveira, J.A. Mendonça, H.L. Staub
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Imbalance and disfuntion in regulatory T-cells (Tregs) and IL-17 producer lymphocytes (Th17) have been implicated in the pathogenesis of rheumatoid arthritis (RA). Gray scale synovial proliferation (GS), power Doppler signal (pD) and bone erosions seen on high resolution muskuloskeletal ultrasound (MSUS) are hallmarks of destructive articular disease. <h3>Objectives</h3> The present study was undertaken to evaluate the association of peripheral Tregs and Th17 with MSUS findings in RA. <h3>Methods</h3> 90 RA patients (1987 ACR criteria) treated with disease-modifying antirheumatic drugs (DMARDs) were included in this prospective cross-sectional study. A blood sample was taken just before clinical and ultrasonographic evaluation. Lymphocytes were isolated and immunophenotyped by flow cytometry to investigate regulatory FoxP3+ T cells and IL-17+ cells. MSUS (MyLab 60, Esaote, Genova, Italy, linear probe 6–18 MHz) was performed consecutively by two ultrassound-trained rheumatologists on the wrists, 2th and 3th metacarpophalangeal and 2th and 3th proximal interphalangeal joints of both hands. GS and pD were searched using a semi-quantitative scale (0–3). Bone erosions were classified as present or absent. The sum of the individual joint scores for GS and pD (score 10) was calculated and used to correlate with clinical and laboratory data. Disease acitivity and disability were measured using Disease Activity Score in 28 joints (DAS28) and Health Assessment Questionnaire (HAQ), respectively. Mann-Whitney test, Kruskal-Wallis test and Spearman correlation coefficient (r<sub>S</sub>) were used for statistical analysis. Inter-rater agreement was tested using the weighted <i>kappa</i> statistic (WKS) and intraclass correlation (ICC). <h3>Results</h3> Clinical and demographic features were: mean age, 55.8 ±11 years; female gender, 79%; Caucasians, 84%; positive rheumatoid factor by nephelometry, 63%; median (interquartile range) disease duration 6 (2–13) years; mean ± SD DAS28, 4.28±1.64; mean ± SD HAQ score, 1.11±0.85. WKS for erosions was 1, and ICC for GS- and pD-score10 were 0.964 (95%CI 0.899 to 0.986) and 0.859 (0.646 to 0.941), respectively. There was no significant association of bone erosions, GS- and pD-score10 with peripheral Tregs and Th17 cells (P&gt;0.25 for all tests). Tregs but not Th17 cells were significantly associated with DAS28 level of disease activity (figure 1). <h3>Conclusions</h3> In this first study addressing MSUS features and lymphocytes subtypes in established RA, data did not support an association of circulating Tregs and Th17 lymphocytes with inflammatory and structural damage findings on MSUS. <h3>Disclosure of Interest</h3> None declared
Reduction in Inpatient Central Line Associated Blood Stream Infection Post Implementation of Bundled Care Measures in Patients with Benign and Malignant Hematological Conditions in a Single Pediatric Institution
Authors: Anupam Verma, Lauri Linder, Elizabeth D Knackstedt, Cheryl Gerdy, Rouett Abouzelof, Richard S. Lemons
Journal: Blood (2015)
S50 Monocytes from IPF patients show pre-conditioned pro-repair features
Authors: E Fraser, K Blirando, V St.Noble, R Benamore, R Hoyles, A Benlahrech, LP Ho
Journal: Thorax (2016)

<h3>Introduction</h3> The central mechanism in IPF is a dysfunctional alveolar epithelial-fibroblast interaction resulting in an aberrant repair process. This defect is influenced by other immune processes; one of these is the macrophage pathway. Macrophages are heterogeneous immune cells that can control all phases of the repair process. ‘M2’ or ‘reparative’ macrophages have anti inflammatory and reparative phenotype, with high scavenger activities. We investigate how monocytes (precursors of monocyte-derived lung macrophages) might contribute to fibrogenesis in IPF. <h3>Methods</h3> 35 IPF patients (25 sampled while stable and 10 with AE-IPF) diagnosed according to the 2011 ATS/ERS/JRS/ALAT guidelines, with ‘definite’ or ‘probable’ IPF and age and gender-matched healthy controls were recruited over a one-year period. Those with emphysema greater than 25%, current smokers and malignancy were excluded. Lung function and CT fibrosis score1 were performed. Phenotype and function of purified monocytes and monocyte-derived macrophages (MDMs) were determined using qPCR and multi-flow cytometry for selected M1 and M2 genes and proteins (M1 – CD64 M2 – CD163 and CD200R by FACS; and 26 M1 and M2 macrophage markers against three house keeping genes). The ability of MDMs to phagocytose (using pHrodo method) and ROS content (using H2DCFDA assays) ex vivo were also examined. <h3>Results and discussion</h3> Circulating monocyte levels were significantly higher in IPF compared to healthy controls (p &lt; 0.001) and correlated negatively with lung function (FVC r = −0.6, p = 0.003) and CT fibrosis score (r = 0.45, p = 0.007). IPF monocytes displayed higher M2:M1 ratio profile compared to healthy controls – with higher <i>IL10, CD163, IL1R2, FGL2</i> and lower <i>TNFa and CXCL10 </i>gene expression. When these monocytes were differentiated to macrophages (MDMs) ex vivo, IPF macrophages showed a significantly higher level of M2 markers and CD14 expression, reduced phagocytosis and produce lower levels of ROS –supporting M2 and pro-repair phenotype. <h3>Conclusions</h3> Our data show that circulating monocytes in IPF are elevated compared to age-matched controls, correlate positively with disease severity, and are different from those found in age-matched healthy controls. They have pro-repair, M2-like features and differentiate to pro-repair monocyte-derived macrophages and may contribute to the aberrant repair process in IPF. <h3>Reference</h3> Best AC, <i>et al</i>. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. <i>Radiology</i> 2008; <b>246</b>:935–40.
Long-Term Follow-up of the Randomized JALSG AML 201 Study Comparing High Dose Ara-C Therapy with Conventional Consolidation Therapy in Adult Acute Myeloid Leukemia (AML)
Authors: Shuichi Miyawaki, Shigeki Ohtake, Shin Fujisawa, Hitoshi Kiyoi, Katsuji Shinagawa, Noriko Usui, Kohichi Miyamura, Miki Nishimura, Yasushi Miyazaki, Kazuhiro Nishii, Tadashi Nagai, Takahisa Yamane, Masafumi Taniwaki, Masatomo Takahashi, Fumiharu Yagasaki, Yukihiko Kimura, Norio Asou, Sumihisa Honda, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno
Journal: Blood (2008)
Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors
Authors: Eric J. Chow, Kara L. Cushing-Haugen, Guang-Shing Cheng, Michael Boeckh, Nandita Khera, Stephanie J. Lee, Wendy M. Leisenring, Paul J. Martin, Beth A. Mueller, Stephen M. Schwartz, K. Scott Baker
Journal: Journal of Clinical Oncology (2017)

Purpose To compare the risks of serious health outcomes among hematopoietic cell transplantation (HCT) survivors versus a matched population of patients with cancer who did not undergo HCT, where the primary difference may be exposure to HCT. Methods Two-year HCT survivors treated at a comprehensive cancer center from 1992 through 2009 who were Washington State residents (n = 1,792; 52% allogeneic and 90% hematologic malignancies) were frequency matched by demographic characteristics and underlying cancer diagnosis (as applicable) to non-HCT 2-year cancer survivors, using the state cancer registry (n = 5,455) and the general population (n = 16,340) using driver’s license files. Late outcomes for all three cohorts were ascertained from the state hospital discharge and death registries; subsequent cancers were ascertained from the state cancer registry. Results After median follow-up of 7.1 years, HCT survivors experienced significantly greater rates of hospitalization compared with matched non-HCT cancer survivors (280 v 173 episodes per 1,000 person-years, P &lt; .001) and greater all-cause mortality (hazard ratio [HR], 1.1; 95% CI, 1.01 to 1.3). HCT survivors had more hospitalizations or death with infections (10-year cumulative incidence, 31% v 22%; HR, 1.4; 95% CI, 1.3 to 1.6) and respiratory complications (cumulative incidence, 27% v 20%; HR, 1.4; 95% CI, 1.2 to 1.5). Risks of digestive, skin, and musculoskeletal complications also were greater among HCT versus non-HCT cancer survivors. The two groups had similar risks of circulatory complications and second cancers. Both HCT and non-HCT cancer survivors had significantly greater 10-year cumulative incidences of all major organ-system outcomes versus the general population. Conclusion History of HCT was associated with late morbidity and mortality among cancer survivors. In particular, clinicians who care for HCT survivors should be aware of their high rates of late respiratory and infectious complications.
Absorption, Metabolism, and Excretion of Quizartinib (AC220), a FLT3 Tyrosine Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, in Healthy Male Volunteers
Authors: Jianke Li, Gayle Bresnahan, Guy Gammon, Madhu Sanga, Christine Hale, Tadashi Hashimoto, Stanley Gill, Joyce James
Journal: Blood (2012)
FRI0436 Fatigue Is Associated with Work Productivity Impairment in Uk Patients with Axial Spondyloarthritis (AXSPA): A Cross-Sectional Observational Study:
Authors: S. Espahbodi, P. Bassett, W. Tillett, C. Cavill, J. Hole, M. Freeth, A. Thomas, R. Sengupta
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Many patients with axSpA experience work disability (WD: not working due to axSpA) which is preceded by impairment whilst working (presenteeism), absenteeism, and overall work productivity loss (WPL). Studies addressing these and health-related factors are few, with only one done in a UK sample. <h3>Objectives</h3> To determine key factors associated with absenteeism, presenteeism, WPL, and daily activity impairment (other than employed work) in UK patients with axSpA using standardized measures. <h3>Methods</h3> In a cross-sectional, observational study, during visits to the Royal National Hospital for Rheumatic Diseases axSpA clinic, 490 patients completed validated questionnaires for: (1) Work productivity using the Work Productivity and Impairment questionnaire (WPAI) which produces 4 measures: absenteeism, presenteeism, WPL and activity impairment; (2) Health-related disease factors using: BASDAI, BASFI, BASMI, Jenkins Sleep scale, Patient Global Assessment (PGA) for disease activity, back pain at night, back pain at any time, EQ-5D for mobility, self-care ability, usual daily activities, pain/discomfort, anxiety/depression, EQ-VAS for Health State Today, FACIT for fatigue in the last week scale, and the Margolis Pain Diagram. Statistics package STATA V. 13.1 was used for analyses. Univariate and multivariate linear and logistic regression were applied to determine associations between WPAI measures and health-related factors. <h3>Results</h3> Of 490 patients, 301 (61%) provided WPAI measurements, 261 (53%) were in employment, 76% were male, 87% HLA-B27+, mean (±SD) years (i) age of first symptoms 21.5 (8.8), (ii) age at diagnosis 30.8 (11.7), (iii)disease duration 21.7 (13.0), and 29% were receiving biologics. Mean scores: BASDAI 3.8 (2.2), BASFI 4.0 (2.7), BASMI 3.8 (2.1), Jenkins 13.0 (2.7), PGA 3.9 (2.6), PGA night pain 3.3 (2.6), PGA pain anytime 3.6 (2.6), FACIT 34 (12), EQ-VAS 63 (22), Margolis pain 8.7 (6.9). Mean WPAI scores for absenteeism were=5.1% (19.2), presenteeism=22% (24.3), WPL=23.2% (25.7), activity impairment=34.8% (27.3). <h3>Conclusions</h3> Work productivity and activity impairment are associated with fatigue, disease activity, and functional ability in UK patients with axSpA. The strong association of fatigue with work disability and activity impairment emphasize the need to measure and better understand the impact of fatigue in axSpA. <h3>Disclosure of Interest</h3> None declared
Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.
Authors: Nicholas J. Donato, Ji Wu, Ling-Yuan Kong, Feng Meng, Francis Lee, Moshe Talpaz
Journal: Blood (2005)
In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).
Authors: Asher Alban Chanan-Khan, Swaminathan Padmanabhan, Kena C. Miller, Paula Pera, Laurie DiMiceli, Noreen Ersing, Paul Wallace, Michael Rickert, Carl Porter
Journal: Blood (2005)
Late Appearance of t(9;22) at Relapse, in an Adolescent with an Homozygous 9p Deletion T-ALL.
Authors: Vassilios Papadakis, Stefanos Papadhimitriou, Anna Paisiou, Chrysoula Belesi, Agapi Parcharidou, Natalia Tourkantoni, Constantina Sambani, George Paterakis, Sophia Polychronopoulou
Journal: Blood (2006)
Pifithrin-μ Prevents Cisplatin-Induced Chemobrain by Preserving Neuronal Mitochondrial Function
Authors: Gabriel S. Chiu, Magdalena A. Maj, Sahar Rizvi, Robert Dantzer, Elisabeth G. Vichaya, Geoffroy Laumet, Annemieke Kavelaars, Cobi J. Heijnen
Journal: Cancer Research (2016)

Abstract Cognitive impairment, termed chemobrain, is a common neurotoxicity associated with chemotherapy treatment, affecting an estimated 78% of patients. Prompted by the hypothesis that neuronal mitochondrial dysfunction underlies chemotherapy-induced cognitive impairment (CICI), we explored the efficacy of administering the small-molecule pifithrin (PFT)-μ, an inhibitor of mitochondrial p53 accumulation, in preventing CICI. Male C57BL/6J mice injected with cisplatin ± PFT-μ for two 5-day cycles were assessed for cognitive function using novel object/place recognition and alternation in a Y-maze. Cisplatin impaired performance in the novel object/place recognition and Y-maze tests. PFT-μ treatment prevented CICI and associated cisplatin-induced changes in coherency of myelin basic protein fibers in the cingular cortex and loss of doublecortin+ cells in the subventricular zone and hippocampal dentate gyrus. Mechanistically, cisplatin decreased spare respirator capacity of brain synaptosomes and caused abnormal mitochondrial morphology, which was counteracted by PFT-μ administration. Notably, increased mitochondrial p53 did not lead to cerebral caspase-3 activation or cytochrome-c release. Furthermore, PFT-μ administration did not impair the anticancer efficacy of cisplatin and radiotherapy in tumor-bearing mice. Our results supported the hypothesis that neuronal mitochondrial dysfunction induced by mitochondrial p53 accumulation is an underlying cause of CICI and that PFT-μ may offer a tractable therapeutic strategy to limit this common side-effect of many types of chemotherapy. Cancer Res; 77(3); 742–52. ©2016 AACR.
Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell Receptors
Authors: Francesco Maura, Carlo Visco, Elisabetta Novella, Ilaria Giaretta, Giacomo Tuana, Luca Agnelli, Marta Lionetti, Sonia Fabris, Francesca Guidotti, Gianluigi Reda, Giuseppe Gritti, Wilma Barcellini, Luca Baldini, Antonino Neri, Francesco Rodeghiero, Agostino Cortelezzi
Journal: Blood (2011)
Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Authors: Kanti R. Rai, Joseph O. Moore, Thomas E. Boyd, Loree M. Larratt, Anatoliy K. Golenkov, Benjamin Koziner, Asher Chanan-Khan, R. G. Bociek, Loretta M. Itri
Journal: Blood (2004)
SP0146 3D Doppler Ultrasound Findings in Healthy Wrist and Finger Tendon Sheaths – Can Feeding Vessels Lead To Misinterpretation in Doppler-Detected Tenosynovitis?
Authors: M. Ammitzbøll-Danielsen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Introduction</h3> To investigate the presence of feeding vessels in or in close proximity to extensor and flexor tendon sheaths at the wrists level and in finger flexor tendon sheaths in healthy controls, using 3D ultrasound (US), which may cause pitfalls in order to ensure correct interpretation of Doppler signals when diagnosing tenosynovitis. <h3>Method</h3> Forty healthy participants (20 women and 20 men in the age 23–67 years) without prior history of arthritis, tendon diseases or present pain in their hands were included. Twenty participants had 3D Doppler US of the 2nd and 3rd finger and twenty of the right wrist. US was carried out using a GE Logiq E9 unit with a 3D US probe. The colour Doppler settings were according to published recommendation. <h3>Results</h3> The feeding vessels in or in close proximity to the tendon sheaths were found in the flexor and extensor tendons sheaths at least once in each participant. No significant difference in feeding vessels was seen between the radial and carpal level in the wrist (p=0.06) or between the 2nd and 3rd flexor tendon sheath (p=0.84). <h3>Conclusion</h3> Doppler findings in or in close proximity to the tendon sheaths were common in wrists and fingers in healthy participants. These feeding vessels can be a source of error, not only due to their presence but also because they may be interpreted as being inside the tendon sheath due to blooming and reverberations artefacts. These vessels should be taken into consideration when diagnosing Doppler tenosynovitis. <h3>Disclosure of Interest</h3> None declared
Wnt3 Signaling Augments integrinβ1-Dependent Adhesion-Mediated Drug Resistance of Multiple Myeloma in Autocrine and Paracrine Manner.
Authors: Masayoshi Kobune, Kazuyuki Murase, Satoshi Iyama, Tsutomu Sato, Yutaka Kawano, Shohei Kikuchi, Koji Miyanishi, Rishu Takimoto, Junji Kato
Journal: Blood (2008)
Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles.
Authors: Laura Mosca, Luca Agnelli, Ivo Kwee, Sonia Fabris, Domenica Ronchetti, Katia Todoerti, Marta Lionetti, Donata Verdelli, Lucia Nobili, Luca Baldini, Fortunato Morabito, Giorgio Lambertenghi Deliliers, Francesco Bertoni, Antonino Neri
Journal: Blood (2007)
SP0151 Clinical Diagnosis of Large Vessel Vasculitis
Authors: M.A. Cimmino
Journal: Annals of the Rheumatic Diseases (2016)

Defining the clinical features of large vessel vasculitiS (LVV) is not easy because their boundaries are not completely clear, their symptoms are very often unspecific, and the correlation between clinical features and imaging, the gold standard of diagnosis, is unpredictable. LVV include giant cell arteritis (GCA), Takayasu9s arteritis (TA), isolated ascending aortitis, PMR-associated LVV, retroperitoneal fibrosis, periaortitis, inflammatory abdominal aneurisms, relapsing polychondritis, and IgG4-related diseases. The organs/tissues affected are various, as in most vasculitides, resulting in symptoms and signs localized to the joints, muscles, eye, brain, kidney, skin and lungs. An interplay between autoimmune and atherosclerosis-associated inflammation is probably at work. Systemic symptoms, including fever, weight loss, malaise, fatigue, night sweats, and depression are often present and may represent the only signs of the disease. At clinical examination, bruits may be present on auscultation. Acute phase reactants are generally unreliable especially for follow-up. Diagnosis relies on imaging, including CE-CT, CE-MRI, and PET/CT or PET/MRI. Vessel biopsy is fundamental to confirm the diagnosis although rarely performed in non-temporal arteritis LVV. Although it is commonly believed that GCA and TA cannot be distinguished by histology, adventitia is relatively spared in TA and commonly damaged in GCA. As in most other rheumatic conditions, the clinician should consider disease activity and damage, although in this case the two entities are not easy to separate. There are no outcome measures specifically developed for LVV, although disease activity has been measured by BVAS, ITAS 2010, and DEI-Tak, each showing some weakness. Damage consists mainly in stenotic or aneurismatic lesions of the vessels, which can appear also long intervals after inflammation has subsided. For this reason, follow-up of patients should continue long-term even if the disease has been apparently cured. LVV are highly detrimental to the patients, who cannot understand the origin of their symptoms, a situation sometimes shared with the attending clinician since the diagnostic delay may be very long. In addition, long periods of asymptomatic disease, with on-going damage, are not rare. Disease-specific patients reported outcomes have not been developed in these conditions, and are a field open to research. <h3>Disclosure of Interest</h3> None declared
In Reply:
Authors: Sandro Pignata, Francesco Perrone, Massimo Di Maio, Ciro Gallo, Sabino De Placido
Journal: Journal of Clinical Oncology (2005)

Յ 10 U/mL [best], 11 to 20 U/mL, and 21 to 30 U/mL [worst]) was better than complete response at discriminating between treatments of differing efficacy. 2Therefore, we suggest that further stratification of patients according to CA125 nadir values is potentially important and may better define the efficacy of topotecan as consolidation therapy in advanced ovarian cancer.
Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM).
Authors: Xavier Leleu, Eeckhoute Jerome, Xiaoying Jia, Anne-Sophie Moreau, Aldo M. Roccaro, Mena Farag, Antonio Sacco, Evdoxia Hatjiharissi, Hai T. Ngo, Judith Runnels, Abdelkareem Azab, Feda Azab, Zachary Hunter, Peter Sportelli, Steven P. Treon, Teru Hideshima, Kenneth C. Anderson, Irene M. Ghobrial
Journal: Blood (2007)
Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).
Authors: Paul Richardson, Robert L. Schlossman, Constantine S. Mitsiades, Nikhil C. Munshi, Kathleen Colson, Deborah Doss, Mary McKenney, Karen Hande, Svetlana Gorelik, Laura Lunde, Anna Stepanek, Andrea Freeman, Karyn Dinand, Stephen Hayes, Reggie Michelle, Keith Doucet, Diane Warren, Nicholas Mitsiades, Victoria M. Richon, Judi Chiao, Kenneth C. Anderson
Journal: Blood (2004)
Risk Factors of HLA-Haploidentical Transplantation Using the Combination of Unmodified Marrow and CD6-Depleted G-CSF Mobilized Blood Cells.
Authors: Hans-Jochem Kolb, Iris Bigalke, Johanna Tischer, Wolfgang Hill, Christine Falk, Belinda Simoes, Christoph Schmid, Georg Ledderose
Journal: Blood (2005)
Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary intervention
Authors: PS Monraats, FR de Vries, EP Slagboom, AH Zwinderman, MP de Maat, WR Agema, Lmt Hart, R de Winter, PA Doevendans, J Waltenberger, RR Frants, A van der Laarse, E Vandewall, JW Jukema
Journal: Circulation (2005)
Gemtuzumab Ozogamicin-Based Salvage, Followed by Allogeneic Hematopoietic Stem Cell Transplantation, Is Highly Effective in Young Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Relapse
Authors: Marie-Anne Hospital, Christian Recher, Xavier Thomas, Emmanuelle Tavernier, Bruno Lioure, Cécile Pautas, Aurore Perrot, Thorsten Braun, Thomas Cluzeau, Jean-Valère Malfuson, Jerome Tamburini, Céline Berthon, Alexis Magda, Chantal Himberlin, Stephane de Botton, Edouard Randriamalala, Isabelle Plantier, Madalina Uzunov, Philippe Rousselot, Norbert Ifrah, Herve Dombret, Nicolas Boissel
Journal: Blood (2011)
Serum Heavy Metal Levels in Patients with Ineffective Erythropoiesis and the Effect of Chelation on Heavy Metal Levels
Authors: Turan Bayhan, Sule Unal, Eyup Cirak, Onur Erdem, Cemal Akay, Ibrahim Eker, A. Murat Tuncer, Mualla Cetin, Fatma Gumruk
Journal: Blood (2015)